CTNNB1 (catenin beta 1) is a member of the WNT signaling pathway and component of cadherin-based adherens junctions. Imbalance of beta-catenin is implicated in cancer progression and metastasis. Simple CTNNB1 variants are seen in 8% of all tumors, including 40% of soft tissue tumors, 5% of colorectal cancers, 4% of melanomas, and 2% of lung cancers. Certain variants are diagnostics for specific soft tissue tumor types. CTNNB1 variants may qualify for clinical trials involving CTNNB1 inhibitors, PDPK1 inhibitors, and/or Tankyrase inhibitors.